Marker TherapeuticsMRKR
Market Cap: $25.9M
About: Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Employees: 8
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
28% more capital invested
Capital invested by funds: $8.54M [Q1] → $10.9M (+$2.37M) [Q2]
0.21% more ownership
Funds ownership: 22.32% [Q1] → 22.52% (+0.21%) [Q2]
0% more funds holding
Funds holding: 28 [Q1] → 28 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for MRKR.